HSK7653 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
Status:
Recruiting
Trial end date:
2022-08-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy of HSK7653 (as monotherapy) compared with
placebo after 24 weeks, and the safety (up to 52 weeks) of HSK7653 in Chinese patients with
Type 2 diabetes who are insufficient glycaemic control with diet and exercise.
Phase:
Phase 3
Details
Lead Sponsor:
Sichuan Haisco Pharmaceutical Group Co., Ltd Sichuan Haisco Pharmaceutical Group Co., Ltd.